New York, USA, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Global Nicotine Replacement Therapy Market is Predicted to Exhibit Remarkable Growth at a CAGR of ~7% by 2030 | DelveInsight The nicotine replacement therapy market is mainly driven by increased smoking cessation programs, heightened health awareness, and the rising incidence of cancer due to ongoing tobacco use through cigarettes, pipes, cigars, and other forms in both developed and developing nations. DelveInsight’s Nicotine Replacement Therapy Market Insights report provides the current and forecast market analysis, individual leading nicotine replacement therapy companies’ market shares, challenges, nicotine replacement therapy market drivers, barriers, trends, and key market nicotine replacement therapy companies in the market.
Key Takeaways from the Nicotine Replacement Therapy Market Report As per DelveInsight estimates, North America is anticipated to dominate the global nicotine replacement therapy market during the forecast period. In the application segment of the nicotine replacement therapy market, the gums category had a significant revenue share in the year 2023. Notable nicotine replacement therapy companies such as Cipla Ltd.
, Johnson & Johnson Services, Inc., GLENMARK PHARMACEUTICALS LTD., Pfizer Inc.
, Rubicon Research Pvt. Ltd., Sparsha Pharma International Pvt Ltd.
, GSK plc, Philip Morris Products S.A., JB Pharma, PL Developments, Dr Reddy’s Laboratories Ltd.
, and Rusan Pharma Limited, and several oth.
